BR0308737A - Pró-drogas de fosfato de fluoroxindóis - Google Patents

Pró-drogas de fosfato de fluoroxindóis

Info

Publication number
BR0308737A
BR0308737A BR0308737-9A BR0308737A BR0308737A BR 0308737 A BR0308737 A BR 0308737A BR 0308737 A BR0308737 A BR 0308737A BR 0308737 A BR0308737 A BR 0308737A
Authority
BR
Brazil
Prior art keywords
fluoroxindole
phosphate prodrugs
enantiomer
phosphate
prodrugs
Prior art date
Application number
BR0308737-9A
Other languages
English (en)
Inventor
Kevin W Gillman
Piyasena Hewawasam
William D Schmitz
Omar D Lopez
John E Starrett
David P Provencal
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0308737A publication Critical patent/BR0308737A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"PRó-DROGAS DE FOSFATO DE FLUOROXINDóIS". A presente invenção refere-se a novos derivados de fosfato tendo a Fórmula (I) geral, em que a ligação ondulada (b) representa o racemato, o enanciómero (R) ou o enanciómero (S) e A, B, R^ 1^, R^ 2^, R^ 3^, R^ 4^, m e n são como definidos aqui, ou um sal ou solvato não-tóxico, farmaceuticamente aceitável, dos mesmos, e são úteis no tratamento de distúrbios que são sensíveis à abertura dos canais de potássio.
BR0308737-9A 2002-03-20 2003-03-20 Pró-drogas de fosfato de fluoroxindóis BR0308737A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36601002P 2002-03-20 2002-03-20
PCT/US2003/008613 WO2003080047A1 (en) 2002-03-20 2003-03-20 Phosphate prodrugs of fluorooxindoles

Publications (1)

Publication Number Publication Date
BR0308737A true BR0308737A (pt) 2005-01-11

Family

ID=28454740

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308737-9A BR0308737A (pt) 2002-03-20 2003-03-20 Pró-drogas de fosfato de fluoroxindóis

Country Status (21)

Country Link
US (1) US6930100B2 (pt)
EP (1) EP1485085A4 (pt)
JP (1) JP4359150B2 (pt)
KR (1) KR100951499B1 (pt)
CN (1) CN100384820C (pt)
BR (1) BR0308737A (pt)
CA (1) CA2479256A1 (pt)
CO (1) CO5611143A2 (pt)
GE (1) GEP20074230B (pt)
HR (1) HRP20040853A2 (pt)
IL (2) IL164022A0 (pt)
IS (1) IS7456A (pt)
MX (1) MXPA04008999A (pt)
NO (1) NO20044442L (pt)
NZ (1) NZ535365A (pt)
PL (1) PL372413A1 (pt)
RS (1) RS81904A (pt)
RU (1) RU2312857C2 (pt)
UA (1) UA77296C2 (pt)
WO (1) WO2003080047A1 (pt)
ZA (1) ZA200407337B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
US6916937B2 (en) * 2003-02-03 2005-07-12 Bristol-Myers Squibb Company Carbohydrate prodrugs of fluorooxindoles
US7169803B2 (en) * 2004-03-15 2007-01-30 Bristol-Myers Squibb Company N-substituted prodrugs of fluorooxindoles
US7253167B2 (en) 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
BRPI0606318B8 (pt) 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
CN101282979B (zh) * 2005-09-13 2011-09-21 卫材R&D管理有限公司 稳定性被改善的含有磷酸氯甲酯衍生物的组合物及其制备方法
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
WO2009100090A1 (en) * 2008-02-05 2009-08-13 Merck & Co., Inc. Prodrugs of cgrp receptor antagonist
US8188119B2 (en) * 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
CA2766033C (en) * 2009-06-25 2016-09-20 Alkermes, Inc. Prodrugs of nh-acidic compounds
AU2010266018B2 (en) 2009-06-25 2014-01-09 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
NZ604423A (en) 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
CN114380799A (zh) 2015-07-06 2022-04-22 吉利德科学公司 Cot调节剂及其使用方法
PE20211305A1 (es) 2018-01-05 2021-07-20 Cybrexa 1 Inc Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas
JP7384812B2 (ja) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド アリピプラゾール投与戦略
WO2019173380A1 (en) * 2018-03-05 2019-09-12 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
JP2022541747A (ja) 2019-07-10 2022-09-27 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
US11634508B2 (en) 2019-07-10 2023-04-25 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
JP7446475B2 (ja) 2020-04-02 2024-03-08 ギリアード サイエンシーズ， インコーポレイテッド Ｃｏｔ阻害剤化合物を調製するためのプロセス
EP3912625A1 (en) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
US5187173A (en) * 1991-12-27 1993-02-16 Sterling Winthrop Inc. 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
CA2317008C (en) 1997-12-31 2009-01-20 The University Of Kansas Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
DE69912250T2 (de) * 1998-01-29 2004-07-29 Bristol-Myers Squibb Co., Wallingford Phosphorylierte derivate des diaryl 1,3,4 oxadiazolon

Also Published As

Publication number Publication date
NO20044442L (no) 2004-10-19
US6930100B2 (en) 2005-08-16
JP2005526097A (ja) 2005-09-02
IL164022A (en) 2008-04-13
US20030195169A1 (en) 2003-10-16
EP1485085A4 (en) 2007-03-14
PL372413A1 (en) 2005-07-25
IL164022A0 (en) 2005-12-18
MXPA04008999A (es) 2004-12-07
CA2479256A1 (en) 2003-10-02
WO2003080047A1 (en) 2003-10-02
RU2004131201A (ru) 2005-05-10
RS81904A (en) 2007-02-05
GEP20074230B (en) 2007-11-12
RU2312857C2 (ru) 2007-12-20
HRP20040853A2 (en) 2004-12-31
KR100951499B1 (ko) 2010-04-07
AU2003215017A1 (en) 2003-10-08
ZA200407337B (en) 2006-02-22
CN100384820C (zh) 2008-04-30
CO5611143A2 (es) 2006-02-28
KR20040106293A (ko) 2004-12-17
CN1652769A (zh) 2005-08-10
UA77296C2 (en) 2006-11-15
NZ535365A (en) 2006-07-28
EP1485085A1 (en) 2004-12-15
IS7456A (is) 2004-09-17
JP4359150B2 (ja) 2009-11-04

Similar Documents

Publication Publication Date Title
BR0308737A (pt) Pró-drogas de fosfato de fluoroxindóis
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
BR0307998A (pt) Hidroxietilaminas substituìdas
BRPI0408561A (pt) métodos para manufatura de 2'-desoxi-59-l-nucleosìeos
ATE464299T1 (de) Neues phenylalaninderivat
BR0206381A (pt) Derivados do ácido fumárico como inibidor de nf-kappab
MY117896A (en) Quinazoline derivatives
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
BR0115452A (pt) Compostos tendo atividade fungicida e processos para fabricação e uso dos mesmos
BRPI0411900A (pt) compostos antivirais e métodos
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
ES2179071T3 (es) Agentes vasodilatadores perifericos que comprenden como principio activo derivados de la piperidina 4-amino n-acilada.
BR0205889A (pt) Pirazolopirimidinas como agentes tepapêuticos
NO20012567L (no) Azepinoindolderivater, fremstilling og anvendelse derav
BR0307071A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
EA200100678A1 (ru) N-уреидоалкил-пиперидины в качестве модуляторов активности рецепторов хемокинов
DK0694547T3 (da) 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propandiolderivat
DE602004031410D1 (de) Inden derivate als pharmazeutika
BR9916807A (pt) Antagonistas de 5ht1 para terapia antidepressiva
PT1056754E (pt) Derivados fosfatados de 1,3,4-oxadiazolona de diarilo
BR9909870A (pt) Pirrolidinas como inibidores de neuraminidases
ES2101373T3 (es) Tetrahidrociclopent(b)indol-metaminas y compuestos relacionados, un procedimiento para su preparacion y su uso como medicamentos.
BR0317719A (pt) Derivados de fosforamida
BR0214529A (pt) compostos terapêuticos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 31/40, A61P 25/06

Ipc: A61K 31/40 (2011.01), A61P 25/06 (2011.01)

B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A, 10A E 11A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.